Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program
2024年3月1日 - 2:00AM
ビジネスワイヤ（英語）
ANIMUS program: development of proprietary
methods using AI to optimize molecules derived from our Nanocyclix®
technology, for faster selection of drug candidates
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63 ;
Mnemonic : ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancer, announces today that it has received notification of the
allocation of financial support from the Deep Tech Development
Fund.
The funding is granted through a combination of grants and a
repayable advance to finance R&D investment. This support is
financed by the French government with funds from the Programme
d'Investissement d'Avenir (PIA4) or the Fonds pour l'Innovation et
l'Industrie (FII),and aims to finance the research and development
phases of breakthrough innovation, prior to its industrial and
commercial launch.
The ANIMUS program (Ai-boosted NanocyclIx
platforM drUg diScovery) is based on the
development of proprietary methods using Artificial Intelligence to
accelerate the optimization of molecules developed using our
Nanocyclix® technology, in order to select drug candidates faster.
The ANIMUS program is supported exclusively by OPM.
OPM has currently a unique Nanocyclix® macrocycle collection of
over 12,000 molecules, all of which are kinase inhibitors. Having
carried out extensive characterization of these molecules, OPM now
has an annotated database that is unique in the industry, which is
an exclusive asset for applying Machine Learning and Deep Learning
methods to optimize the Drug Discovery process.
The main purpose of ANIMUS is to develop proprietary
technologies to improve the efficiency of the drug discovery
process at OPM, based on Nanocyclix® technology. This involves the
development of AI approaches enabling, first, the systematic
optimization of all parameters at each DMTA1 cycle in order to
reduce the number of cycles required to identify drug candidates
and, second, the use of NCX generative molecule design to assess a
very large number of molecules in silico at the design phase.
The Deep Tech Development Fund has awarded €745,000 to ANIMUS
for a total project cost of €1.49 million and a 36-month project
period.
Philippe Genne, Chairman and CEO of Oncodesign Precision
Medicine, said: “Following the recent allocation of ERDF
funding for the COMETE project, which should enable us to start
developing our first systemic therapy products, we are delighted to
have been granted Deeptech funding focused on our Nanocyclix
technology. AI is a technology that is now essential for
effectively optimizing the Drug Discovery process. We initially
integrated it in OncoSNIPER for the discovery of new therapeutic
targets, and in Nanocyclix the aim is to achieve more rapidly the
development of more powerful and specific kinase inhibitors. We are
capitalizing on our 15 years of R&D to develop Nanocyclix, its
library and our AI skills. These projects are key to our
technological development and the construction of our Precision
Medicine platform. This funding is another strong recognition of
invaluable support from our regional institutional environment and
it highlights the dynamic behind the development of biotechnologies
and, in particular, Precision Medicine in the Bourgogne Franche
Comté region.”
Jan Hoflack, Co-founder and Chief Medical Officer of
Oncodesign Precision Medicine, added: “We have been developing
Nanocyclix® technology since 2010: these are small kinases
inhibitors macrocyclic molecules. Their 3-dimensional shape enables
them to interact with their target with great efficacy and
specificity. Since 2010, development programs based on Nanocyclix®
have been designed, in partnership and internally, leading to 3
molecules in clinical phase today. The multitude of data obtained
on more than 12,000 molecules represents a treasure of information
that we are going to exploit using AI methods (Machine Learning and
Deep Learning) to accelerate our Drug Discovery process. The 3D
aspect, which is essential for Nanocyclix®, is currently poorly
explored by AI methods. Furthermore, the small macrocyclic
molecules developed with Nanocyclix® are difficult to generate
efficiently using current methods. The use of AI on our proprietary
database in this context has the potential to accelerate
significantly the discovery of clinical candidates while reducing
the costs associated with this process.”
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers.
OPM's innovative technologies are (i) OncoSNIPER for the
selection of therapeutic targets using artificial intelligence;
(ii) Nanocyclix® for the design and selection of macrocyclic small
molecule kinase inhibitors and (iii) Promethe for the design and
selection of radiolabeled biological molecules for systemic
radiotherapy.
From these technologies, OPM has built a portfolio of
therapeutic products. A first drug candidate based on the
Nanocyclix® technology entered the clinical phase in 2022, in
partnership with SERVIER (which exercised its option for an
exclusive worldwide license on the program) to treat Parkinson's
disease. OPM-101 is OPM's second candidate to enter the clinic, in
the treatment of chronic immuno-inflammatory diseases. Finally, OPM
is also collaborating with Servier to discover new therapeutic
targets for the treatment of pancreatic adenocarcinoma based on its
OncoSNIPER technology. In addition, OPM is seeking a partner for
Florepizol, a radiotracer specific for the mutated EGFR target,
which has successfully completed Phase I. Finally, OPM has a
significant portfolio of early-stage projects with Nanocyclix® and
Promethe in oncology. With this portfolio of molecules and
diversified therapeutic targets, OPM's mission is to discover
effective therapies to treat resistant and advanced cancers. Based
in Dijon, at the heart of the university and hospital cluster, OPM
has 25 employees.
More info at: oncodesign.com
1 Design- Make-Test-Analyze
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229228930/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)310
451 820 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
過去 株価チャート
から 4 2024 まで 5 2024
Oncodesign Precision Med... (EU:ALOPM)
過去 株価チャート
から 5 2023 まで 5 2024
